Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

http://www.wikidata.org/entity/Q39866155

about

Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants Plasma vs heart tissue concentration in humans - literature data analysis of drugs distribution.Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution.Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.Fluconazole penetration in cerebral parenchyma in humans at steady state Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.Medical imaging in new drug clinical development.Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques.Influence of local radiotherapy on penetration of fluconazole into human saliva.CNS pharmacokinetics of antifungal agents.Microdosing studies in humans: the role of positron emission tomography.Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy.Tissue penetration of antifungal agents.Fluconazole penetration into the pancreas.Expression of ubiquitin gene in Microsporum canis and Trichophyton mentagrophytes cultured with fluconazole.Identification of Fungal Species in Brain Tissue from Alzheimer's Disease by Next-Generation Sequencing.Plasma and tissue concentrations of fluconazole and their correlation to breakpoints.The role of positron emission tomography in pharmacokinetic analysis.Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis

P2860

Q30435365-4B0723B6-1605-4255-A764-2B71D1E1BF2F Q30909481-B440D531-6189-473B-AD13-D8D69E2CB86E Q31046210-B0FB93DC-AED9-4C11-958D-376E24066644 Q33695030-C162D152-A86F-49FF-86FA-E0E94055E0BB Q35114601-29E55948-5E11-43F4-A78D-31C30D80FE36 Q35135644-E0AFF1DB-3267-4FD5-A724-D0D4A6C248DA Q35136891-286CB738-B976-461D-9F87-52753BA7CF81 Q35667744-19B6EC35-E7AB-41F6-82FD-D3975113ED37 Q35825795-879A990C-61B1-4BF0-8FF2-5D7A7BCF76E7 Q35904456-92EB6CEB-C057-499D-8EC9-858578AD9E3B Q36909333-CD043A71-95DC-4868-8897-6334E3BFB398 Q37093858-90E16F3E-D2B4-4DB9-8005-9DC5781B2966 Q37263320-AF37454E-42AC-4BD2-9838-B2DC02CAFE42 Q37544911-E3EE67F9-3C0D-444E-B104-C34575EF1CB8 Q39475094-567A85DF-0520-4F4F-8D18-3D088A55F9FA Q39478273-8F7761ED-36EC-4F4A-8A23-518E924589A6 Q40260689-A71BF7D0-20E6-4F14-A312-872339B2A54C Q41566153-ECC6DE28-D46E-42A6-96E4-F913527D2260 Q41676775-2F988D8A-507C-400A-95E6-9E583F6A1408 Q56910086-8CE27B1E-DD38-46F1-A2BE-7BB605EB80C0

P2860

Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

http://www.wikidata.org/entity/Q39866155

description

1993 nî lūn-bûn

@nan

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

1993年论文

@zh

1993年论文

@zh-cn

name

Pharmacokinetics of 18F-labele ...... positron emission tomography.

@en

Pharmacokinetics of 18F-labele ...... positron emission tomography.

@nl

type

label

Pharmacokinetics of 18F-labele ...... positron emission tomography.

@en

Pharmacokinetics of 18F-labele ...... positron emission tomography.

@nl

prefLabel

Pharmacokinetics of 18F-labele ...... positron emission tomography.

@en

Pharmacokinetics of 18F-labele ...... positron emission tomography.

@nl

P1433

Q39866155-6BC59485-2197-4DEE-B8E2-A144226E3AE9

P1476

Q39866155-71AA243E-8520-4363-9BF8-8B73A4D17D07

P2093

Q39866155-16F03929-7805-4D94-9971-D4C2CCB53D4D

Q39866155-62DF1941-4A9C-4E5A-9C31-73D2F63D4A25

Q39866155-7483A979-13AD-42EC-BDC6-470E47DCCFCB

Q39866155-756F7562-1809-43B9-9D5B-8531BDA35826

Q39866155-92F02335-ACF4-430F-B457-808B2E7381BD

Q39866155-B030003E-8557-4146-81E5-E6F449487F87

Q39866155-D3F71922-294B-4DF8-94DE-481CADC611B0

Q39866155-DB24EB39-442C-48B8-A943-DD41F230E708

Q39866155-E09D69CA-CE8D-4EC4-A0AB-7F89B00E46CC

Q39866155-F1FC868C-39B3-4380-A6C4-382CD80A603A

P2860

Q39866155-06293793-2541-4B1F-B406-8DDE6C380960

Q39866155-1FC2FD4F-3404-4066-A3F9-F2F9CD0C4D01

Q39866155-2166C391-535D-47C7-8A03-FB17F39E3488

Q39866155-2A97BAC0-9923-4362-BFAC-20C0F378FFB2

Q39866155-2C6DC1A7-9898-4693-9E2C-ECFE598DE683

Q39866155-36514D7E-0B1C-4172-A7CB-7DDEF77C034E

Q39866155-4AAB553C-E38C-4EC0-A9FB-142FB528E7BA

Q39866155-52662119-3AA6-4E4F-8720-BF5B97DA473A

Q39866155-5FB11D45-42CB-482A-977E-8A553B2484B3

Q39866155-722B7995-26B1-4C38-BE44-9EB70C777D56

P304

Q39866155-BC4828A4-C2FE-43DE-91EC-2FCF35E360B5

P31

Q39866155-4AAC48A1-426E-48CE-8F85-E55BB43F963F

P356

Q39866155-A5737C80-7242-41C8-A4B0-49CE60EFD6BF

P407

Q39866155-97C0811F-7FE1-4A21-9C78-D00838A46437

P433

Q39866155-B860A418-D9B3-45D7-B287-51503365169C

P478

Q39866155-8A86B11C-DEF7-4E6C-AB96-16A68F5C6D4B

P577

Q39866155-C893C9BF-0B59-4D92-B01B-861635114F92

P698

Q39866155-2AF32456-5016-454D-9311-7D3F70A9D51D

P921

Q39866155-5BC01D81-56DB-4F15-B7B0-5CD351606451

P932

Q39866155-13BD2DE5-3694-48DC-9DEF-714B258DA813

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics of 18F-labele ...... positron emission tomography.

@en

P2093

Alpert NM

http://www.w3.org/2001/XMLSchema#string

Callahan RJ

http://www.w3.org/2001/XMLSchema#string

Correia JA

http://www.w3.org/2001/XMLSchema#string

Fischman AJ

http://www.w3.org/2001/XMLSchema#string

Livni E

http://www.w3.org/2001/XMLSchema#string

Ray S

http://www.w3.org/2001/XMLSchema#string

Rubin RH

http://www.w3.org/2001/XMLSchema#string

Sinclair I

http://www.w3.org/2001/XMLSchema#string

Strauss HW

http://www.w3.org/2001/XMLSchema#string

Webb D

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis

Sputum levels of fluconazole in humans.

Azole antifungal agents: emphasis on new triazoles.

Pharmacokinetics and tissue penetration of fluconazole in rabbits

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo

Azoles and AIDS.

Toxicological profile and safety evaluation of antifungal azole derivatives.

Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.

Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action.

P304

1270-1277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.37.6.1270

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

1993-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8328777

http://www.w3.org/2001/XMLSchema#string

P921

human subject research

P932

187952

http://www.w3.org/2001/XMLSchema#string